ClinicalTrials.gg

Fallopian Tube Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 835 studies for Fallopian Tube Neoplasms across more than 10 countries. 131 are recruiting or about to start. 287 of them are mainly about Fallopian Tube Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,009 studies for Fallopian Tube Neoplasms. How that becomes 833 here

This page counts the studies the registry files under Fallopian Tube Neoplasms, and those it files under no condition that list Fallopian Tube Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,009Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4List Fallopian Tube Neoplasms as a condition, but the registry did not file them under itMost often written as “Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum” (3), “Stage II Fallopian Tube Cancer AJCC v6 and v7” (1), and “Stage IIA Fallopian Tube Cancer AJCC v6 and v7” (1). The registry filed them under other conditions only, most often Carcinoma, Ovarian Epithelial (3) and Anemia (1).
  3. −172Match it another way33 name it in the title and 139 by a synonym or other text the search reads.
  4. 833The count on this page5 of them list Fallopian Tube Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
421
Terminated
111
Recruiting
106
Active, not recruiting
80
Status unknown
55
Withdrawn
34

Phase

Phase 2
383
Phase 1
269
Phase 3
113
Early Phase 1
18
Phase 4
2

Where

United States
589
Canada
86
United Kingdom
76
Spain
70
China
59
Italy
57

Who develops what

Add Fallopian Tube Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 27 programs from 20 companies, 9 with this as their studies’ main aim; 15 with a live phase 3 study; 10 primary completions in the next 12 months. Compare Beijing Biotech, Sichuan Biokin Pharmaceutical and AbbVie here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PaclitaxelRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2026
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Paclitaxel” · registered May 2026
  • NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Paclitaxel” · registered Oct 2025
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed1113 studies
liposomal doxorubicinRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Oct 2026
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Jul 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered May 2026
  • NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Liposomal Doxorubicin” · registered Apr 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Pegylated liposomal doxorubicin (PLD)” · registered Oct 2025
Johnson & Johnson21% of its industry studiesEU: Baxter Healthcare Corporation (EMA 1996) + 2 others1011 studies
BevacizumabRecent, repeated
Evidence
  • NCT07859215 · Genmab · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07851025 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07816666 · AstraZeneca · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07811271 · BeOne Medicines · Phase 3 · live · background · “Bevacizumab” · registered Sep 2026
  • NCT07776691 · Merck & Co., Inc · Phase 3 · live · background · “Bevacizumab” · registered Aug 2026
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others915 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Jul 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Carboplatin” · registered Oct 2025
  • NCT07024784 · AbbVie · Phase 2 · live · background · “Carboplatin” · registered Jun 2025
  • NCT06915025 · Imunon · Phase 3 · live · background · “Carboplatin” · registered Apr 2025
  • NCT06087289 · Kancera AB · Phase 2 · background · “Carboplatin” · registered Sep 2023
Eli Lilly and Company16% of its industry studies89 studies
TopotecanRecent, repeated
Evidence
  • NCT07926048 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Oct 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Topotecan” · registered May 2026
  • NCT07545460 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Topotecan” · registered Apr 2026
  • NCT07213804 · Eli Lilly and Company · Phase 3 · live · comparator · “Topotecan” · registered Oct 2025
  • NCT06751485 · Alphamab Oncology · Phase 3 · live · comparator · “Topotecan” · registered Dec 2024
GlaxoSmithKline55% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 1 generic authorized78 studies
GemcitabineRecent, repeated
Evidence
  • NCT07743164 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2026
  • NCT07604766 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered May 2026
  • NCT06834672 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “paclitaxel/Gemcitabine/Liposomal doxorubicin” · registered Feb 2025
  • NCT06619236 · Genmab · Phase 3 · live · comparator · “Gemcitabine” · registered Sep 2024
  • NCT05870748 · Sutro Biopharma, Inc. · Phase 3 · comparator · “Gemcitabine” · registered May 2023
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed45 studies
niraparibRecent, repeated
Evidence
  • NCT06915025 · Imunon · Phase 3 · live · background · “Niraparib” · registered Apr 2025
  • NCT05335993 · CanariaBio Inc. · Phase 2 · live · background · “Niraparib” · registered Feb 2022
  • NCT05198804 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 2 · background · “Niraparib” · registered Dec 2021
GlaxoSmithKline53% of its industry studiesUS: GlaxoSmithKline (FDA 2023)EU: GlaxoSmithKline (EMA 2017)33 studies
olaparibRecent, repeated
Evidence
  • NCT07024784 · AbbVie · Phase 2 · live · background · “Olaparib” · registered Jun 2025
  • NCT06915025 · Imunon · Phase 3 · live · background · “Olaparib” · registered Apr 2025
AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014)22 studies
pegfilgrastimRecent, repeated
Evidence
  • NCT06690775 · TORL Biotherapeutics, LLC · Phase 2 · live · background · “Pegfilgrastim (drug)” · registered Nov 2024
  • NCT05870748 · Sutro Biopharma, Inc. · Phase 3 · background · “Pegfilgrastim” · registered May 2023
Amgen29% of its industry studiesUS: Amgen (FDA 2002) + 7 othersEU: Amgen (EMA 2002) + 12 others22 studies

21 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
mirvetuximab soravtansineApproved: US 2022 · EU 2024☆ Track1 live phase-3 study: NCT05445778AbbVie
rinatabart sesutecan☆ Track3 live phase-3 studies: NCT06619236, NCT07604766, NCT07859215Genmab
Anti-HER2 Antibody-drug Conjugate IBI354☆ Track1 live phase-3 study: NCT06834672Innovent Biologics, Inc.
raludotatug deruxtecan☆ Track2 live phase-3 studies: NCT07791732, NCT06161025Daiichi Sankyo
torvutatug samrotecan☆ Track2 live phase-3 studies: NCT07851025, NCT07816666AstraZeneca

The 5 in phase 3 with the nearest primary completion, of 27 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (10)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.mirvetuximab soravtansine · AbbVie · Phase 2 main aimNCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer — primary endpoint: Overall Response Rate (ORR) · 125 enrolled
  • 30 Dec 2026 est.anbenitamab repodatecan · Alphamab Oncology · Phase 3 named, not the main aimvs Paclitaxelvs Topotecanvs DoxorubicinNCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer — primary endpoint: Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1 · 430 enrolled
  • 17 Feb 2027 est.Dual-target CAR-NK cell product, Lymphodepleting chemotherapy · Beijing Biotech · Phase 2 named, not the main aimNCT07480954 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 36 enrolled

7 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Fallopian Tube Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here PARP inhibitors 11 open · Antimitotic agents 9 open · Antibody-drug conjugates (ADCs) 6 open · Angiogenesis inhibitors 5 open · Immune checkpoint inhibitors 5 open

Coming up

71studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger. 6 (6%) take children under 18. 80 (75%) are for women only and 0 (0%) for men only; 1 (1%) take healthy volunteers.

Recruiting studies that take each age, of 106
AgeWomenMen
105 (5%)3 (3%)
18104 (98%)26 (25%)
30106 (100%)26 (25%)
40106 (100%)26 (25%)
50106 (100%)26 (25%)
65106 (100%)26 (25%)
75106 (100%)26 (25%)
8594 (89%)26 (25%)

Across all 835 studies, recruiting or not: 5% stop at 75 or younger and 1% at 65; 7% take children; 82% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Fallopian Tube Neoplasms studies take

Of 125 phase 2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 56 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 154 mo36–83 · 96 studies42 mo31–57 · 31 studies69 mo38–87 · 65 studies
Phase 1/270 mo56–110 · 37 studies——
Phase 256 mo42–90 · 125 studies—63 mo45–91 · 98 studies
Phase 359 mo38–109 · 54 studies——
Interventional, no phase83 mo27–94 · 28 studies——
Observational64 mo35–151 · 45 studies—74 mo35–151 · 37 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 835. Browse all 835 → or search them.